Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis C

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 17 articles: HTML format

Single Articles

December 2023
1. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
   New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
   J Gastroenterol. 2023;58:1252-1260.
   PubMed     Abstract available
   
   
   October 2023
2. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
   Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
   J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
   PubMed     Abstract available
   
   
   March 2023
3. SHIMAKAMI T, Setoyama H, Oza N, Itakura J, et al
   Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.
   J Gastroenterol. 2023;58:257-267.
   PubMed     Abstract available
   
   
   February 2023
4. MIZUOCHI T, Iwama I, Inui A, Ito Y, et al
   Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study.
   J Gastroenterol. 2023 Feb 15. doi: 10.1007/s00535-023-01968.
   PubMed     Abstract available
   
   
   
5. NAKAGAWA M, Asahina Y, Kakinuma S, Okamoto R, et al
   Correction: Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
   J Gastroenterol. 2023 Feb 9. doi: 10.1007/s00535-023-01961.
   PubMed    
   
   
   
6. KOTANI K, Enomoto M, Uchida-Kobayashi S, Tamori A, et al
   Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
   J Gastroenterol. 2023 Feb 2. doi: 10.1007/s00535-023-01963.
   PubMed     Abstract available
   
   
   December 2022
7. NAKAGAWA M, Asahina Y, Kakinuma S, Okamoto R, et al
   Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
   J Gastroenterol. 2022 Dec 30. doi: 10.1007/s00535-022-01940.
   PubMed     Abstract available
   
   
   July 2022
8. GENDA T, Ichida T, Tanaka E, Mochida S, et al
   Allograft liver failure awaiting liver transplantation in Japan.
   J Gastroenterol. 2022;57:495-504.
   PubMed     Abstract available
   
   
   January 2022
9. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
   Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
   J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
   PubMed     Abstract available
   
   
   
10. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    PubMed     Abstract available
    
    
    August 2021
11. CHEN C, Yang RX, Xu HG
    STING and liver disease.
    J Gastroenterol. 2021;56:704-712.
    PubMed     Abstract available
    
    
    May 2021
12. ITAKURA J, Kurosaki M, Setoyama H, Simakami T, et al
    Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
    J Gastroenterol. 2021;56:470-478.
    PubMed     Abstract available
    
    
    December 2020
13. OCHI H, Hiraoka A, Hirooka M, Koizumi Y, et al
    Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    J Gastroenterol. 2020 Dec 5. pii: 10.1007/s00535-020-01747.
    PubMed     Abstract available
    
    
    November 2020
14. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available
    
    
    October 2020
15. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    PubMed     Abstract available
    
    
    
16. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available
    
    
    November 2019
17. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
    J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.